Bristol-Myers Squibb Co. (BMY): Price and Financial Metrics


Bristol-Myers Squibb Co. (BMY): $58.07

0.48 (+0.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BMY POWR Grades


  • BMY scores best on the Value dimension, with a Value rank ahead of 97.2% of US stocks.
  • The strongest trend for BMY is in Stability, which has been heading up over the past 52 weeks.
  • BMY's current lowest rank is in the Momentum metric (where it is better than 4.46% of US stocks).

BMY Stock Summary

  • With a market capitalization of $127,971,519,517, Bristol Myers Squibb Co has a greater market value than 98.04% of US stocks.
  • Bristol Myers Squibb Co's stock had its IPO on January 1, 1986, making it an older stock than 92.73% of US equities in our set.
  • The volatility of Bristol Myers Squibb Co's share price is greater than that of just 6.28% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Bristol Myers Squibb Co are AMGN, BP, DE, COP, and RIO.
  • Visit BMY's SEC page to see the company's official filings. To visit the company's web site, go to www.bms.com.

BMY Valuation Summary

  • BMY's EV/EBIT ratio is -44.2; this is 250.85% lower than that of the median Healthcare stock.
  • Over the past 243 months, BMY's price/sales ratio has gone down 2.6.
  • BMY's price/sales ratio has moved down 2.6 over the prior 243 months.

Below are key valuation metrics over time for BMY.

Stock Date P/S P/B P/E EV/EBIT
BMY 2021-08-31 3.3 4.0 -29.3 -44.2
BMY 2021-08-30 3.4 4.1 -29.4 -44.4
BMY 2021-08-27 3.3 4.0 -29.1 -44.1
BMY 2021-08-26 3.4 4.0 -29.3 -44.3
BMY 2021-08-25 3.4 4.1 -29.6 -44.6
BMY 2021-08-24 3.4 4.1 -30.0 -45.1

BMY Growth Metrics

  • Its year over year revenue growth rate is now at 38.07%.
  • Its 2 year cash and equivalents growth rate is now at 196.09%.
  • The 5 year price growth rate now stands at 1.4%.
Over the past 30 months, BMY's revenue has gone up $21,823,000,000.

The table below shows BMY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 44,384 12,773 -5,079
2021-03-31 42,810 13,982 -6,219
2020-12-31 42,518 14,052 -9,015
2020-09-30 39,395 12,420 -44
2020-06-30 34,862 12,757 -563
2020-03-31 31,006 10,571 954

BMY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BMY has a Quality Grade of B, ranking ahead of 81.66% of graded US stocks.
  • BMY's asset turnover comes in at 0.38 -- ranking 125th of 681 Pharmaceutical Products stocks.
  • PAHC, ACUR, and XLRN are the stocks whose asset turnover ratios are most correlated with BMY.

The table below shows BMY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.380 0.759 -0.071
2021-03-31 0.353 0.744 -0.072
2020-12-31 0.339 0.723 -0.123
2020-09-30 0.307 0.713 0.062
2020-06-30 0.314 0.696 0.050
2020-03-31 0.334 0.681 0.058

BMY Price Target

For more insight on analysts targets of BMY, see our BMY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $80.06 Average Broker Recommendation 1.48 (Moderate Buy)

BMY Stock Price Chart Interactive Chart >

Price chart for BMY

BMY Price/Volume Stats

Current price $58.07 52-week high $69.75
Prev. close $57.59 52-week low $56.66
Day low $57.90 Volume 9,010,300
Day high $58.60 Avg. volume 10,671,198
50-day MA $62.72 Dividend yield 3.4%
200-day MA $64.04 Market Cap 129.04B

Bristol-Myers Squibb Co. (BMY) Company Bio


Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations. As of September 2020, it had the total revenue of $39.3 billion. (Source:Wikipedia)


BMY Latest News Stream


Event/Time News Detail
Loading, please wait...

BMY Latest Social Stream


Loading social stream, please wait...

View Full BMY Social Stream

Latest BMY News From Around the Web

Below are the latest news stories about Bristol Myers Squibb Co that investors may wish to consider to help them evaluate BMY as an investment opportunity.

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS APPH, BMY, WDH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

NEW ORLEANS, LA / ACCESSWIRE / October 18, 2021 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C., remind investors of pending deadlines in the following securities class action lawsuits:Waterdrop Inc.

Yahoo | October 18, 2021

Bristol Myers (BMY) Gets Positive CHMP Opinion for Zeposia in UC

The CHMP gives a positive opinion on, and recommends granting approval to Bristol Myers' (BMY) Zeposia for the treatment of adults with moderately to severely active ulcerative colitis.

Yahoo | October 18, 2021

Celebrating the Science That Transforms Patients' Lives

By Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Global Drug Development

Yahoo | October 18, 2021

2 Top Biotech Stocks to Buy in October

Since the consumer price index (an inflation indicator) rose 5.3% year over year in August, it's as important as ever to buy dividend stocks that can raise their dividend ahead of inflation to gain purchasing power. Here are two biotech stocks that not only can stay ahead of inflation through strong dividend increases but that are fairly priced and offer enticing 3% yields. Bristol Myers Squibb (NYSE: BMY) is the first biotech stock that investors should consider purchasing in October.

Yahoo | October 18, 2021

APPH, BMY, EAR, HYZN SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set

NEW ORLEANS, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AppHarvest, Inc. (APPH)Class Period: 5/17/2021 - 8/10/2021 Lead Plaintiff Motion Deadline: November 23, 2021SECURITIES FRAUD To learn more, visit https://www.ksfcounsel.com/cases/nasdaqgs-apph/ Hyzon Motors Inc. (NasdaqGS: HYZN, HYZNW) f/k/a Decarbonizatio

Yahoo | October 16, 2021

Read More 'BMY' Stories Here

BMY Price Returns

1-mo -2.96%
3-mo -14.34%
6-mo -10.66%
1-year -0.20%
3-year 25.55%
5-year 34.71%
YTD -4.18%
2020 0.41%
2019 27.74%
2018 -12.90%
2017 7.71%
2016 -13.49%

BMY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full BMY Dividend History

Continue Researching BMY

Here are a few links from around the web to help you further your research on Bristol Myers Squibb Co's stock as an investment opportunity:

Bristol Myers Squibb Co (BMY) Stock Price | Nasdaq
Bristol Myers Squibb Co (BMY) Stock Quote, History and News - Yahoo Finance
Bristol Myers Squibb Co (BMY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8691 seconds.